Clinical Trials Logo

Clinical Trial Summary

High sodium intake is a significant risk factor for hypertension. Recently, animal studies connect high sodium intake to the gut-immune axis and highlight the gut microbiome as a potential therapeutic target to counteract salt-sensitive conditions and hypertension. The objective of this project is to determine the effects of high salt intake on gut microbiota composition and gut intestine barrier integrity, leading to increased BP in humans. The investigators also hypothesize that high salt intake affects the gut microbiome in a sex-specific manner. In this pilot study, The investigators also test whether telehealth or in-person nutritional coaching help to decrease dietary sodium intake and improve diet quality


Clinical Trial Description

The investigators will conduct a randomized, double-blind, placebo-controlled trial in normotensive and stage 1 hypertensive drug naïve participants (age 18-50 years, equal distribution of blacks and whites, and males and females, BP <140/90 mmHg). The average intake of sodium in the American diet is 3,400 mg per day. The average recommended dose is 2,300 mg per day. Eligible participants will be enrolled and provided with one-hour in-person/telehealth nutritional counseling at the GPI to reduce their sodium intake by 1,100 mg per day to achieve the sodium intake of 2,300 mg/day. Participants will then be randomized to receive either placebo or salt pills of 2,000 mg per day for four weeks while continuously receiving weekly telehealth nutritional counseling. The salt group's sodium intake will be 4,300 mg per day, while the sodium intake in the placebo group will be 2,300 mg per day. Participants will have a follow-up visit at six months after the 4-week sodium intervention. Participants will be tested four times (Figure 1). Participants will receive the first 1-hour in-person/telehealth nutrition counseling at GPI (baseline) and three weekly telehealth nutrition counseling during the 4-week intervention period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04958148
Study type Interventional
Source Augusta University
Contact Haidong Zhu, MD, PhD
Phone 706-721-4534
Email hzhu@augusta.edu
Status Recruiting
Phase Early Phase 1
Start date December 18, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT03812614 - Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support N/A
Completed NCT03650166 - High BP and Home Monitoring Experience (HoME) Study N/A
Recruiting NCT02908139 - Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients N/A
Completed NCT01622400 - Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk N/A
Completed NCT00659672 - Effect of Whey Protein on Blood Pressure N/A
Completed NCT00473681 - Intervention Study to Control High Blood Pressure for Korean American N/A
Completed NCT03542240 - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome N/A
Active, not recruiting NCT05526092 - OAT-GUT-BRAIN: Effects of Oats and Rice on Comprehensive Health of Metabolically Challenged Individuals N/A
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Recruiting NCT03753204 - Salt-Sensitivity and Immunity Cell Activation Phase 1/Phase 2
Not yet recruiting NCT04064281 - The Healthy Cantonese Diet on Cardiometabolic Syndrome N/A
Completed NCT04479384 - The Immediate Effect of an Osteopathic Manual Treatment on Blood Pressure in Adults With Hypertension - a Pilot Study. N/A
Completed NCT04082819 - MediBeat - HeartBeat Observation Trial N/A
Completed NCT03555344 - Effect of Mantra on Hypertensive Patients N/A
Withdrawn NCT03319823 - Treating Nocturnal Hypertension and Nocturia in African American Men Phase 4
Completed NCT00689819 - Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients N/A
Completed NCT00417170 - Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome Phase 2
Completed NCT00130156 - Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Phase 4
Completed NCT05808556 - Sticker Pad Containing Essential Oil in Volunteer With High Blood Pressure N/A
Recruiting NCT05321368 - A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities N/A